Introduction
============

Chronic obstructive pulmonary disease (COPD) is one chronic inflammatory disease of the lung that is known to have systemic features, one of which is an increased risk of cardiovascular disease (CVD). There is now considerable evidence about associations between COPD and CVD. Cardiovascular events become an important cause of death in COPD. However, the mechanisms responsible for the increased risk of CVD in COPD patients are not known. Further elucidation of these mechanisms will provide novel targets for treatment of both the lung and cardiovascular complications of COPD.

Hydrogen sulfide (H~2~S) is a gas with smell of rotten eggs, it was discovered to be the third gasotransmitter after nitric oxide (NO) and carbon monoxide (CO) ([@B26]). The production of H~2~S in mammalian cells is attributable to three endogenous enzymes: cystathionine β-synthase (CBS), cystathionineγ-lyase (CSE) and 3-mercaptopyruvate sulfurtransferase (3-MST) ([@B14]). H~2~S plays an important role in respiratory diseases ([@B5], [@B4]; [@B6]; [@B30]; [@B29]) and CVDs ([@B3]; [@B10]). Homocysteine (Hcy) is the main substrate to generate endogenous H~2~S in the body, high homocysteine is a risk factor in the cardiovascular system ([@B12]; [@B7]; [@B16]; [@B18]). H~2~S and homocysteine are in the same metabolic pathway in the body and play a role in pathophysiological processes of diseases.

Previously we have found that serum H~2~S concentration was increased in patients with stable COPD and decreased in patients with acute exacerbation of COPD (AECOPD) ([@B5]); the imbalance of hydrogen and Hcy was shown in essential hypertensive children ([@B3]). It is not known whether the imbalance of endogenous H~2~S and Hcy is associated with CVD in patients with COPD. Therefore, this study was to explore the metabolic pathway alteration of H~2~S/Hcy in patients with COPD combined with CVD.

Materials and Methods {#s1}
=====================

Study Design
------------

This was a cross-sectional observational study. We collected data on demographics, smoking and medical history via interview or self-administered questionnaires. Dyspnea was quantified by application of the modified Medical Research Council Dyspnea scale (mMRC) which asked respondents to rate dyspnea on a 5-point scale from 0 (absent) to 4 (dyspnea when dressing /undressing). Symptoms were quantified by use of COPD assessment test (CAT). Quality of life in patients with COPD was evaluated by St George's respiratory questionnaire (SGRQ). Lung function tests, sputum were performed.

Subjects
--------

Patients were recruited from clinics at Peking University, Third Hospital between September 2010 and March 2011. We enrolled 51 stable COPD patients. The diagnosis of COPD was made according to the criteria recommended by Global Initiative for Chronic Obstructive Lung Disease (GOLD) guideline ([@B21]). Chronic airflow limitation was defined as forced expiratory volume in 1 s/forced vital capacity (FEV~1~/FVC) \< 70% after using an inhaled bronchodilator, bronchodilator reversibility test revealed an increase in FEV~1~ \< 12% and/or 200 ml below the prebronchodilator FEV~1~ after administration of 400 μg of inhaled salbutamol. Patients with stable COPD had no acute exacerbation of symptoms and upper respiratory tract infection in the 2 months preceding the study. Subjects with concomitant respiratory diseases other than COPD were excluded. COPD subjects were categorized as non-severe (stages I and II) and severe (stages III and IV) according to GOLD stages. All selected patients were divided into COPD group (25 patients) and COPD + CVD group (26 patients). CVD referred to hypertension, coronary heart disease (angina, myocardial infarction), left ventricular failure and cardiac arrhythmia. In COPD + CVD group, 11 patients got hypertension, 5 patients got coronary heart disease, 1 patient got left ventricular failure, and 9 patients got 2 or more CVDs. For each CVD, we diagnosed according to the guidelines ([@B22]). Protocol for this study was approved by the institutional review board of Peking University, Third Hospital (approved number IRB00006761-2012029). Written informed consents were obtained from all participants.

Pulmonary Function Test
-----------------------

Pulmonary function test was performed with a spirometer (Medgraphics, Elite Series DL, St. Paul, MN, United States). FEV~1~, FVC, FEV~1~/FVC, and FEV~1~% predicted were measured in all subjects.

Serum H~2~S, Hcy, hs-CRP, TNF-α, Glucose and Lipids Levels
----------------------------------------------------------

Venous blood samples were obtained from all subjects while fasting, serum was stored at -80°C until further analysis. Serum H~2~S concentration was measured with use of a sulfide-sensitive electrode (Model 9616, Orion Research, Beverly) according to our published literature ([@B5]). Hcy, high sensitive C-reactive protein (hs-CRP) and Tumor necrosis factor α (TNF-α) in serum were measured using commercially ELISA kits (R&D Systems, Minneapolis, MN, United States). Glucose, and lipids (T-CHO, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol) in serum were measured using commercially reagent kits (Merit Choice, Bioengineering, Beijing; or SEKISUI.MEDICAL CO., LTD.).

Induced Sputum Analysis
-----------------------

Sputum was collected and processed as previous described ([@B5]). In brief, all patients inhaled 4% hypertonic saline solution for 15--30 min to induce the sputum plugs from the lower respiratory tract, before that, all patients inhaled 200 μg of salbutamol for avoiding hypertonic saline solution-induced bronchoconstriction. Sputum plugs were incubated with 0.1% dithiothreitol until completely homogenized. After filtering and centrifuging, the cell pellet was resuspended in phosphate-buffered saline solution (PBS), then placed on slides and stained with Wright-Giemsa for differential cell counts of leukocytes.

Statistical Analysis
--------------------

Statistical analyses involved use of SPSS v17.0 (SPSS Inc., Chicago, IL, United States). Continuous variables were expressed as mean ± SD (standard deviation) for normal distribution. Categorical variables were expressed in number (percentage). For comparisons between two continuous variables, the independent two-sample test was used, for categorical variables, X^2^ test was used. Correlation analysis was performed by use of Spearman rank correlation. A two-tailed *P*-value \< 0.05 was considered significant.

Results
=======

Clinical Characteristics and Lung Function between Two Groups
-------------------------------------------------------------

The characteristics and lung function of subjects were shown in **Tables [1](#T1){ref-type="table"}--[3](#T3){ref-type="table"}**. Body mass index (BMI) and waist circumference were higher in COPD + CVD group than in COPD group (**Table [1](#T1){ref-type="table"}**), mMRC, CAT and activity scores were also higher (**Table [2](#T2){ref-type="table"}**). The decrease of lung function was found in COPD + CVD group as compared to the COPD group (**Table [3](#T3){ref-type="table"}**), but the difference was not statistically significant. So patients in COPD + CVD group had worse dyspnea, severer symptoms and worse quality of life.

###### 

Demographics between two groups.

                               COPD            COPD + CVD      *P*
  ---------------------------- --------------- --------------- -------
  Age, year                    67.20 ± 8.58    70.38 ± 7.06    0.153
  No. of male (%)              22 (88.0)       22 (84.6)       0.725
  No. of smoking (%)           20 (80.0)       20 (76.9)       0.789
  No. of current smokers (%)   12 (48.0)       13 (50.0)       0.886
  GOLD stage III-IV, No (%)    11 (44.0)       13 (50.0)       0.668
  Smoking pack-years           27.50 ± 20.71   24.22 ± 25.53   0.618
  BMI (kg/m2)                  21.40 ± 2.71    24.45 ± 2.63    0.000
  Waist circumference (cm)     80.88 ± 5.86    88.65 ± 9.77    0.001
                                                               

COPD, chronic obstructive pulmonary disease; CVD, cardiovascular disease; GOLD, Global Initiative for Chronic Obstructive Lung Disease; BMI, body mass index

.

###### 

Clinical characteristics between two groups.

                   COPD            COPD + CVD      *P*
  ---------------- --------------- --------------- -------
  mMRC score       1.50 ± 0.91     2.35 ± 1.38     0.027
  CAT score        13.50 ± 6.21    17.95 ± 6.47    0.029
  SGRQ scores                                      
  Total score      35.67 ± 16.02   45.75 ± 22.18   0.104
  Symptom score    57.91 ± 17.02   65.16 ± 19.71   0.209
  Activity score   46.26 ± 16.48   62.67 ± 28.06   0.031
  Impact score     24.50 ± 17.87   30.40 ± 22.16   0.346
                                                   

mMRC, modified Medical Research Council Dyspnea scale; SGRQ, St. George's Respiratory Questionnaire; CAT, COPD assessment test

.

###### 

Lung function between two groups.

                      COPD            COPD + CVD      *P*
  ------------------- --------------- --------------- -------
  FEV~1~/FVC (%)      54.48 ± 9.58    51.88 ± 11.83   0.394
  FEV~1~% predicted   56.76 ± 18.62   48.92 ± 15.05   0.106
                                                      

FEV

1

, forced expiratory volume in the first second; FVC, forced vital capacity

.

Glucose and Lipids in Blood
---------------------------

We determined whether the glucose or lipids in blood could be altered in COPD + CVD group. There were no significant differences in blood glucose, T-CHO, TG and LDL-C between two groups, but high density lipoprotein- cholesterol (HDL-C) was lower in COPD + CVD group (1.22 ± 0.21 mmol/L) than in COPD group(1.47 ± 0.35 mmol/L) (**Table [4](#T4){ref-type="table"}**).

###### 

The glucose and lipids between two groups.

                     COPD          COPD + CVD    *P*
  ------------------ ------------- ------------- -------
  Glucose (mmol/L)   5.87 ± 1.36   5.50 ± 0.73   0.313
  T-CHO (mmol/L)     5.20 ± 0.81   4.91 ± 0.89   0.313
  TG (mmol/L)        1.51 ± 0.98   1.72 ± 0.85   0.506
  HDL-C (mmol/L)     1.47 ± 0.35   1.22 ± 0.21   0.023
  LDL-C (mmol/L)     3.11 ± 0.72   2.88 ± 0.58   0.307
                                                 

T-CHO, total cholesterol; TG, triglyceride; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol

.

Cellular Parameters in Sputum and Inflammatory Cytokines in Serum
-----------------------------------------------------------------

Total cells and neutrophils (%) were higher in sputum of COPD + CVD group than those of COPD group, while macrophages (%) was lower, there was no statistical significance in lymphocytes (%) between two groups (**Table [5](#T5){ref-type="table"}**). hs-CRP level in serum from COPD + CVD group (21.97 ± 9.84 ng/ml) was higher than that from COPD group (16.44 ± 5.98 ng/ml), but there was no significant difference in TNF-α level (**Table [5](#T5){ref-type="table"}**). It indicated that the airway inflammation was more obvious in COPD + CVD patients.

###### 

The differentiated cell proportion in sputum and inflammatory cytokines in serum between two groups.

                              COPD             COPD + CVD       *P*
  --------------------------- ---------------- ---------------- -------
  Total cells ( × 10^4^/ml)   184.94 ± 84.37   241.83 ± 72.34   0.037
  Neutrophils (%)             68.00 ± 14.13    77.11 ± 10.82    0.037
  Lymphocytes (%)             10.13 ± 5.3      8.6 ± 5.18       0.406
  Macrophages (%)             21.50 ± 11.24    14.19 ± 5.59     0.019
  hs-CRP (ng/ml)              16.44 ± 5.98     21.97 ± 9.84     0.025
  TNF-α (pg/ml)               7.20 ± 3.52      7.30 ± 5.67      0.950
                                                                

hs-CRP, high sensitive C-reactive protein; TNF-α, Tumor necrosis factor -α

.

H~2~S, Hcy Levels in Serum and H~2~S/Hcy Ratio
----------------------------------------------

H~2~S level in serum from COPD + CVD group (14.91 ± 5.72 μmol/L) was higher than that from COPD group (11.68 ± 3.14 μmol/L) (**Figure [1A](#F1){ref-type="fig"}**), and it was decreased significantly with increasing COPD severity (**Figure [2A](#F2){ref-type="fig"}**); Hcy level from COPD + CVD group (7.76 ± 7.64 μmol/L) was higher than that from COPD group (3.08 ± 3.21 μmol/L) (**Figure [1B](#F1){ref-type="fig"}**), and it was increased significantly with increasing COPD severity (**Figure [2B](#F2){ref-type="fig"}**). We also measured the H~2~S/Hcy ratio and found that H~2~S/Hcy ratio in serum from COPD + CVD group was lower than that from COPD group (**Figure [1C](#F1){ref-type="fig"}**).

![The serum H~2~S, Hcy and H~2~S/Hcy ratio in COPD and COPD + CVD groups. **(A)** Serum H~2~S concentration in both groups; **(B)** Serum Hcy concentration in both groups, **(C)** The ratio of H~2~S/Hcy in both groups. The data are described as mean ± SD. ^∗^*P* \< 0.05 versus COPD.](fphar-08-00624-g001){#F1}

![The H~2~S and Hcy in non-severe and severe groups. **(A)** Serum H~2~S concentration in both groups; **(B)** Serum Hcy concentration in both groups. The data are described as mean ± SD. ^∗^*P* \< 0.05 versus COPD.](fphar-08-00624-g002){#F2}

Correlations among H~2~S, Hcy, H~2~S/Hcy Ratio and Other Variables
------------------------------------------------------------------

**Table [6](#T6){ref-type="table"}** showed the correlations among serum H~2~S, Hcy levels, H~2~S/Hcy ratio and other variables in all subjects. Serum H~2~S level was positively correlated with FEV~1~/FVC, FEV~1~% predicted, lymphocytes (%) and macrophages (%) in sputum, while it was negatively correlated with smoking pack-years and neutrophils (%) in sputum. Serum Hcy level was positively correlated with BMI and total cells in sputum. H~2~S/Hcy ratio was positively correlated with FEV~1~/FVC.

###### 

The correlations among H~2~S, Hcy, H~2~S/Hcy ratio and other variables.

                      H~2~S    Hcy     H~2~S/Hcy                    
  ------------------- -------- ------- ----------- ------- -------- -------
  Smoking pack year   -0.366   0.011   -0.029      0.202   0.070    0.691
  BMI                 0.187    0.207   0.318       0.048   -0.313   0.067
  FEV~1~/FVC          0.338    0.020   -0.280      0.084   0.354    0.037
  FEV1% predicted     0.306    0.036   -0.200      0.222   0.253    0.143
  Cells in sputum                                                   
  Total cells         0.058    0.739   0.389       0.034   -0.392   0.035
  Neutrophils %       -0.369   0.029   0.096       0.612   -0.130   0.503
  Lymphocytes %       0.502    0.002   -0.081      0.672   0.167    0.385
  Macrophages %       0.340    0.045   -0.151      0.425   0.082    0.672
                                                                    

Discussion
==========

In our study, we have identified the imbalance of endogenous H~2~S and Hcy in COPD + CVD. Compared with patients with COPD, patients with COPD + CVD had severer dyspnea, worse symptoms and quality of life, the ratio of endogenous H~2~S/Hcy was lower, they also had obvious local and systemic inflammation reaction.

Chronic obstructive pulmonary disease is an inflammatory disease, there is growing evidence that the inflammatory state associated with COPD is not only confined to the lung but also to the circulation system and non-pulmonary organs. Epidemiological studies indicate that COPD is associated with high frequencies of coronary artery disease, congestive heart failure and cardiac arrhythmia, independent of shared risk factors ([@B22]). Whether they have distinct clinical characteristics is not clear.

In our study, we found that COPD + CVD patients had higher waist circumference and BMI values. BMI is an indicator reflecting the overall obesity; Waist circumference, which reflects abdominal fat content, is an indicator of abdominal obesity. Studies have shown that visceral fat produced more angiotensin, interleukin-6 and plasminogen activator inhibitor than subcutaneous fat did, ([@B25]) it had closer correlation with hypertension, diabetes, metabolic syndrome, ([@B15]) and was more important than BMI as a cardiovascular risk. So higher waist circumference is an obvious risk factor for COPD + CVD patients.

We also found patients with COPD and cardiac comorbidities had severer dyspnea, worse symptoms and quality of life. SGRQ is the most widely used questionnaire in COPD to assess the quality of life, the SGRQ score is related to the prognosis of COPD and considered as an independent risk factor for mortality ([@B8]). mMRC is a commonly used questionnaire to evaluate dyspnea of patients. CAT is a new test questionnaire which covers all aspects such as symptoms, activity and sleep, psychological and social impacts. Induced sputum analysis showed COPD + CVD patients had higher total cells, neutrophils (%) and lower macrophages (%) in sputum, which indicated that the airway inflammation was more obvious in COPD + CVD patients. These results showed that COPD + CVD patients had obvious clinical characteristics and airway inflammation.

Researchers have proposed multiple mechanisms that link coronary heart disease with COPD. Possible pathways include associations with chronic low-grade systemic inflammation, oxidative stress and shared risk factors, such as older age, cigarette smoking and environment pollution. H~2~S is found to be a protective factor in CVDs, ([@B28]; [@B1]; [@B17]) while high Hcy is a risk factor in cardiovascular system ([@B12]; [@B7]; [@B16]; [@B18]). We speculate that the imbalance of endogenous H~2~S/Hcy metabolic pathway plays an important role in the pathogenesis of COPD + CVD. It was reported that the plasma H~2~S/Hcy ratio in children with hypertension was lower than that of control ([@B3]). Plasma H~2~S level was significantly lower in patients with acute coronary syndrome than patients with stable angina pectoris or non-coronary artery disease ([@B10]). We found that serum H~2~S level was significantly increased in COPD + CVD patients and decreased with the severity of COPD. H~2~S level was positively correlated with FEV~1~, FEV~1~/FVC, and FEV~1~% predicted, which was consistent with our previous findings ([@B5]). It was shown that plasma homocysteine was elevated in COPD patients compared to healthy controls, ([@B23]; [@B9]) and elevated with COPD severity ([@B23]). In this study, serum Hcy level was elevated in patients with COPD + CVD and also increased with severity of COPD, which was consistent with previous findings, ([@B23]), however, we found that the ratio of H~2~S/Hcy in COPD + CVD patients was lower, and it was positively correlated with FEV~1~/FVC. These results suggested that the imbalance of H~2~S/Hcy may be a risk factor for COPD + CVD patients. In COPD + CVD patients, whether protein expression or activity of CBS/CSE decreasing need to be explored further.

On the other hand, many studies have shown that H~2~S played a protective role through anti-inflammation and/or antioxidant stress, for example, exerting protective effects in rats of pulmonary fibrosis or acute lung injury ([@B2]; [@B30]; [@B24]). In contrast, high Hcy triggered an inflammatory reaction in vascular muscle cells by promoting CRP production, ([@B20]) induced inflammatory injury in endothelial cells ([@B11]). In COPD + CVD patients, there was higher serum hs-CRP, total cells and neutrophils% in sputum, this indicated more obvious inflammation reaction. Both H~2~S and Hcy levels were increased in patients with COPD and cardiac comorbidities, but H~2~S/Hcy ratio was lower, maybe the higher level of H~2~S is a consequence of increased Hcy, it is a kind of compensation reaction, however, the increased H~2~S was not in proportion to the increased Hcy, the beneficial compensation of H~2~S in body may not inhibit the adverse effect of increased Hcy.

This study also showed that HDL-C was lower in COPD + CVD patients. Hcy level was positively correlated with BMI, which was consistent with the reports of and [@B13] and [@B27] Hcy is also associated with lipid metabolism. In a cohort survey based in Chinese population of a community, it showed that hyperhomocysteinemia was related to increasing risk of low HDL-C and high TG, it predicted that Hcy levels might influence lipid metabolism ([@B19]). Dyslipidemia and overweight are recognized risk factors for CVD. The associations among H~2~S/Hcy, dyslipidemia and overweight may provide other targets for treatments in COPD + CVD patients.

In addition, our previous study showed that smoking can cause the decline of serum H~2~S level, ([@B5]) current study showed that serum H~2~S was negatively correlated with smoking pack-years. It is well known that smoking is a common risk factor for COPD and CVD, leading to oxidative/antioxidant imbalance and systemic inflammation. Decreased H~2~S level may reduce its anti-inflammatory and anti-oxidation capability, resulting in an increased risk for COPD and CVD.

However, our study had some limitations. First, it was a cross-sectional study, without the possibility to properly infer causality. Therefore, we need prospective studies to investigate the role of H~2~S/Hcy in metabolic pathway of COPD + CVD patients for providing some directions in diagnosis and treatment. Second, this study was a pilot study, the samples of each group were a little small, and study subjects were restricted to stable COPD patients without acute exacerbation, so our results cannot be generalized. Last but not least, We didn't include healthy controls in this study, but in our previous study, ([@B5]) we have observed the difference of plasma H~2~S between COPD patients and healthy controls; Also, in other studies, ([@B23]; [@B9]) the difference of Hcy between COPD patients and healthy controls was observed. The objects of this study were to explore the differences of serum H~2~S and Hcy between COPD patients and COPD + CVD patients. Nevertheless, it is a foundation for future large cohort study.

In summary, a plethora of factors may be associated with the increased risks of CVD in COPD. The role of H~2~S/Hcy metabolic pathway and its clinical significance need further exploration. Future exploration of these mechanisms shall provide novel targets for treatment of cardiovascular complications in COPD.
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